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Human cytomegalovirus (HCMV) is the leading viral cause of congenital birth defects
and is responsible for morbidity and mortality in immunosuppressed individuals.
Considerable efforts have been deployed over the last decade to develop a vaccine
capable of preventing HCMV infection. However, in recent clinical trials, vaccines
showed at best modest efficacy in preventing infection. These findings might be
explained by the high level of sequence polymorphism at the genomic level. To
investigate if genomic variation also leads to antigenic variation, we performed a
bioinformatic sequence analysis and evaluated the percentage of conservation at the
amino acid level of all the proteins present in the virion envelope. Using more than
two hundred sequences per envelope glycoprotein and analyzing their degree of
conservation, we observe that antigenic variation is in large part limited to three proteins.
In addition, we demonstrate that the two leading vaccine candidates, the pentamer
and gB complexes, are well conserved at the amino acid level. These results suggest
that despite genomic polymorphism, antigenic variability is not involved in the modest
efficacy observed in the recent clinical trials for a HCMV vaccine. We therefore propose
that next-generation vaccines should focus on stabilizing and refining the gB domains
needed to induce a protective humoral response.
Keywords: human cytomegalovirus, envelope glycoproteins, viral diversity, multiple sequence alignment, protein
sequence analysis, phylogenic analysis
INTRODUCTION
Human cytomegalovirus (HCMV) is a member of the Betaherpesvirinae subfamily of Herpesviridae
and 40–80% of the human adult population is seropositive to HCMV (Kenneson and Cannon,
2007). Primary infection is generally asymptomatic in immunocompetent individuals. Nonetheless,
HCMV establishes lifelong latency in infected individuals (Zhuravskaya et al., 1997), and viral
reactivation in immunosuppressed hosts such as transplant patients and patients with AIDS can
cause severe diseases or lead even to death (Rando et al., 1990). HCMV is also the major cause of
congenital birth defects (0.7% of the newborns) (Kirby, 2016), exceeding fetal alcohol syndrome
and Zika virus infection in industrialized countries. Current antiviral therapies and treatments
with hyperimmune globulin transfusion to control viremia are not efficient (Tandon and Mocarski,
2012). Due to the prevalence, severity and importance of this virus, the United States National
Academy of Medicine considers that obtaining an effective vaccine against HCMV is a top priority
in public health. However, HCMV is a complex virus with a genome encoding at minimum
170 open reading frames (ORFs) (Stern-Ginossar et al., 2012) and expressing at least nineteen
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membrane proteins integral to the virion envelope (Weekes
et al., 2014). These envelope proteins are primarily required
for binding to the host cells, viral entry and, in some cases,
immune evasion by sequestering human chemokines (Frascaroli
et al., 2006; Frascaroli et al., 2018). HCMV broad cellular tropism
(epithelial/endothelial cells, fibroblasts, monocytes/macrophages,
smooth muscle cells, neurons, stromal cells and hepatocytes) is
due to two glycoprotein complexes responsible for the interaction
with specific host cell receptors (Malito et al., 2018; Nguyen
and Kamil, 2018). The gHgLgO (trimer) complex is required for
infection of all cell types and is known to bind the platelet-derived
growth factor receptor α (PDGFRα) expressed on fibroblasts
(Kabanova et al., 2016). The gHgLpUL128pUL130pUL131A
(pentamer) complex is required for viral entry in epithelial,
endothelial and myeloid cells and binds Neuropilin2 (Nrp2)
(Martinez-Martin et al., 2018). Membrane fusion between the
virus and the surface of the host cell is catalyzed by the
glycoprotein B (gB), a class III fusion protein forming a
homotrimer (Burke and Heldwein, 2015; Chandramouli et al.,
2015). Promising HCMV vaccine candidates have been sought
among the viral proteins present in the envelope and in the
tegument layer of the virus (Anderholm et al., 2016). Current
vaccine research is focusing on two protein complexes of
the virion envelope: the gB homotrimer and the pentamer
(Chiuppesi et al., 2017; Wussow et al., 2018). Both complexes
were identified as dominant targets of the humoral immune
response upon infection (Macagno et al., 2010; Kabanova et al.,
2014). Research studies on gB are more advanced compared
to the pentamer, and a vaccine was already tested in phase
I and II clinical trials (Baraniak et al., 2018a; Nelson et al.,
2018b; Schleiss, 2018). The vaccine demonstrated around 50%
efficacy in preventing HCMV acquisition in seronegative women
(Baraniak et al., 2018a; Nelson et al., 2018a). However, antibodies
elicited by the vaccine were only poorly neutralizing (Baraniak
et al., 2018a; Nelson et al., 2018b). To explain these results,
several hypotheses have been proposed: the presence of an
undesired antigenic domain (AD) in the gB antigen used
in the vaccine, the post-fusion conformation of the antigen
injected, but also the sequence diversity observed among the gB
proteins expressed by the different natural circulating HCMV
strains (Renzette et al., 2011, 2017). Indeed, HCMV is described
as being a highly polymorphic virus at the genomic level
(Renzette et al., 2016), and it was shown that sequence diversity
of some proteins impacts the infection outcome (Renzette
et al., 2011; Galitska et al., 2018). To investigate if HCMV
genomic diversity is also leading to antigenic variation of the
proteins belonging to the virion envelope, we used datasets
from publicly available HCMV genomes and performed sequence
diversity analysis.
MATERIALS AND METHODS
Sequences Analysis of HCMV Proteins
Eighteen envelope and membrane protein sequences of HCMV
were obtained from the National Center for Biotechnology
Information (NCBI) Entrez Protein database as of September 18,
2018 (Sayers et al., 2019) and were derived from the following
genes: RL10, UL1, UL4, UL33, UL55, UL73, UL74, UL75,
UL78, UL100, UL115, UL116, UL128, UL130, UL131A, UL132,
US27, and US28. For each protein, the sequences were purged
of duplicates for a given strain, partial sequences (+/− 5
amino acids) and sequences lacking the name of the strain, the
country where it was isolated and/or the collection date. For
downstream analysis, we used on average 240 sequences for each
HCVM protein. Protein sequences were aligned with Clustal 
(Sievers et al., 2011). For a given protein, a matrix presenting
the percentage of amino acids identity between strains was
generated followed by hierarchical clustering using the Heatmap
function from the “ComplexHeatmap” R package (Gu et al.,
2016) (Euclidean metric and complete aggregation method).
The overall mean distances (percentage of mean identity) were
computed with MEGA X (Kumar et al., 2018) with default
parameters. Analyses of the glycoprotein pentamer complex
gHgLpUL128pUL130pUL131A (UL75-UL115-UL128-UL130-
UL131A) and gB (UL55) were conducted by concatenation of
each glycoprotein for a given strain. We used the sequences
of 207 strains containing the pentamer and gB to perform an
evolutionary analysis. The evolutionary history was inferred
by using the Maximum Likelihood method based on the JTT
matrix-based model (Jones et al., 1992), bootstrapped 500 times.
The trees with the highest log likelihood are shown and are
drawn to scale, with branch lengths measured in the number of
substitutions per site. Evolutionary analyses were conducted in
MEGA X. Trees were visualized with iTOL (Letunic and Bork,
2016). Histograms of consensus sequence for the “hot-spots” of
pentamer, gB, gN, and gO were obtained by Jalview software
(Waterhouse et al., 2009). The list of HCMV strains used in this
study is available as (Supplementary Table S1).
RESULTS
Envelope Protein Required for Viral
Tethering Are Well Conserved
Human cytomegalovirus envelope contains four viral G protein-
coupled receptors (vGPCRs), namely pUL33, pUL78, pUS27,
and pUS28 proteins (de Munnik et al., 2015). Among these
four vGPCRs, only pUS28 is functional and possesses structural
similarity to the human chemokine receptors CCR1 and CCR5
(Gao and Murphy, 1994). The pUS28 also binds human CX3CL1
and additional inflammatory chemokines from the CC-family
(Krishna et al., 2018). Analysis by similarity matrix demonstrated
that all vGPCRs are very well conserved (Figure 1A), a result
consistent with the conserved architectural structure of the
GPCRs (Congreve et al., 2017). The vGPCRs have a limited
immunogenicity, due to the minimal exposure of the short
loops that link the seven-(pass)-transmembrane domains. The
glycoprotein M (UL100) together with glycoprotein N (UL73)
forms the gM/gN heterodimer, which is one of the most abundant
protein complexes within the HCMV envelope. Furthermore,
this heterodimer is one of the few envelope proteins conserved
among herpesviruses, thus suggesting an important function in
their biology. Although the latter is not fully understood, the
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complex was shown to be involved in the initial interaction
phases with host cells by binding heparin present on the cellular
envelope (Compton et al., 1993). Interestingly, whereas gM is
extremely conserved with 99% mean identity across strains, gN
is one of the less conserved proteins with only 81% of identity
(Figure 1A). Moreover, gN is extensively modified by O-linked
sugars which contribute to its mass for more than 40 kDa
(Pignatelli et al., 2001). Nevertheless, gN was identified as a target
of neutralizing antibodies (Shimamura et al., 2006), a surprising
result considering its sequence variability and glycosylation status
(Supplementary Figure S1a).
Structural Components of the Virion
Envelope Exhibit a Low Degree of
Conservation
The organization of the viral proteins in the envelope is still poorly
characterized and understood. Most of the proteins from this
group display a very low degree of conservation mean identity
across strains (Figure 1B). The gp1 (UL1) is a glycoprotein with
224 amino acids and whose function remains unclear. However, it
was shown that gp1 contains an Ig-like domain, and disruption
of gp1 in HCMV generates viral growth defects in epithelial
cells but not in fibroblasts (Shikhagaie et al., 2012). The gp48
(UL4) is a 48 kDa glycoprotein whose expression is non-essential
for HCMV replication in cell cultures (Alderete et al., 2001).
The gp42 (UL132) is a highly glycosylated protein of 270 amino
acids, described to be required for cellular endocytosis of the
virus. Furthermore, gp42 is necessary for optimal replication of
the virus (Kropff et al., 2010). The gpTRL10 (RL10) is a 170-amino
acid-long glycoprotein with no function yet identified.
Sequence Diversity of HCMV
Glycoproteins Involved in Viral Entry
Human cytomegalovirus uses two viral ligands for specific and
high affinity interactions with the host cells. The pentamer
complex is required for viral entry in epithelial, endothelial and
myeloid cells (Ryckman et al., 2008a,b), and it represents the
main target of neutralization against HCMV, eliciting extremely
potent neutralizing antibodies (Macagno et al., 2010; Kabanova
et al., 2014). Sequence analysis of the pentamer subunits reveals
an extremely high level of conservation, with a mean identity of
98% (Figure 1C). This degree of conservation could be explained
by the complex folding required to assemble the five subunits
together (Chandramouli et al., 2017). Moreover, the multiple
amino acid contacts occurring between the Nrp2 receptor and
the gL, pUL128, pUL130, and pUL131A subunits also limit
the possibility of antigenic drift (Martinez-Martin et al., 2018).
Surprisingly, the trimeric complex composed of gH, gL, and gO
possesses a low mean percentage of identity. The gO subunit
is responsible for this low degree of conservation, since it is
one of the less conserved envelope glycoproteins of HCMV,
with a mean identity of 81% (Figure 1C). Interestingly, most
of the sequence divergence is located in the N-terminus part
of the protein (Supplementary Figure S1b), which is supposed
to interact with PDGFRα, the cellular receptor of this complex
(Stegmann et al., 2017, 2019). Of note, the pUL116 protein was
recently identified as a binding partner for gH, forming a dimeric
complex of unknown function (Calo et al., 2016). The relatively
high degree of conservation observed for pUL116 might indicate
that the gH/pUL116 complex interacts with host or other viral
proteins. The gB protein is encoded by the highly polymorphic
gene UL55 (Paterson et al., 2002). However, our sequence analysis
revealed a mean identity of 96% at the amino acid level, indicating
that the protein is well conserved across strains (Figure 1D). The
glycoprotein B is necessary for entry in all cell types, making it an
appealing candidate for a HCMV vaccine.
Sequence Diversity of Vaccine
Candidates
The trimer gHgLgO is necessary for cellular entry in all cell types
and represents a potential target for vaccine design. Nonetheless,
the complex glycan shield and the important sequence variation
of gO are likely to represent a major problem for vaccine
development. The gHgL heterodimer represents an interesting
option for vaccine design, since both subunits are well conserved
and characterized. However, immunization experiments in
animal models generated suboptimal neutralization titers
(Kabanova et al., 2014). Therefore, the gB homotrimer and the
pentamer represent the best option for a prophylactic HCMV
vaccine either alone or in combination. Some reports suggested
that gB or pentamer sequence variation could be an issue for
the generation of an efficient vaccine (Renzette et al., 2011). To
gain further insights into gB and pentamer sequence variability,
we used a total of 207 sequences per protein, obtained from
the NCBI Entrez Protein database corresponding to different
strains. This allowed us to generate a phylogenic tree based on
the Maximum Likelihood method for both gB (Figure 2A and
Supplementary Figure S2) and the pentamer (Figure 2B and
Supplementary Figure S3). This analysis demonstrated that
gB sequences are more diverse among strains (Figure 2A and
Supplementary Data S1) compared to the pentamer (Figure 2B
and Supplementary Data S2).
Indeed, analysis of sequence alignment demonstrated that
the pentamer is well conserved, with only one main sequence
variation localized on a short stretch of 30 amino acids (7
to 37) (Figure 3A) corresponding to the gH signal peptide
(Chandramouli et al., 2017). In contrast, sequence variations on
gB were localized on two “hot spots” (Figure 3B). These regions
correspond to amino acids 27 to 70 and amino acids 451 to
483. The distal region (aa 451–483) includes the Furin cleavage
site (Singh and Compton, 2000), and sequence variation of this
site was initially used to classify different gB genotypes (Chou
and Dennison, 1991). However, the relevance of the latter is
not entirely clear concerning the infectivity and classification of
HCMV strains (Stangherlin et al., 2017). The proximal region
(aa 27–70) includes AD-2, which is one of the five antigenic
domains (AD-1, -2, -3, -4 and -5) identified for gB. Interestingly,
only antibodies directed against AD-2, AD-4, or AD-5 are able
to neutralize the virus. Recently, a publication demonstrated that
anti-AD-2 serum titers correlate with protection from viremia
(Baraniak et al., 2018b), information that is highly relevant
for vaccine design. Surprisingly, the crystal structure obtained
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FIGURE 1 | Conservation matrices of HCMV proteins integral to the virion envelope. Percentage of amino acids identity is represented as matrices using hierarchical
clusters from the “ComplexHeatmap” R package. The following proteins are represented: (A) Four viral G protein-coupled receptors (UL33, UL78, US27, and US28)
and two glycoproteins (gN and gM); (B) Glycoproteins with unknown function gp1, gp42, gp48, and gpTRL10; (C) Protein UL116, proteins composing the pentamer
(gH, gL, pUL128, pUL130, and pUL131A) and the trimer (gH, gL, and gO) complexes; (D) gB.
FIGURE 2 | Phylogenic tree of gB and the pentamer complexes. 207 HCMV strains containing both gB and the proteins composing the pentamer were used for
analysis. (A,B) Phylogenic analysis of the amino acid sequences by Maximum Likelihood method, bootstrapped 500 times, conducted by MEGA X. (A) gB tree and
(B) pentamer complex tree.
from gB in its post-fusion conformation (Burke and Heldwein,
2015; Chandramouli et al., 2015) was not performed on the full
extracellular domain and did not include the AD-2 sequence. The
latter was removed, as it was believed to be unstructured and
flexible in the post-fusion conformation adopted by gB.
DISCUSSION
Human cytomegalovirus is the most common cause of viral-
induced birth defects in industrialized countries. There is no
treatment or vaccine clinically available today. The virion
envelope protein gB is essential for viral entry and represents
a major target of the humoral immune response following
infection. gB vaccines were found to be safe and immunogenic
in clinical phase I and II studies, eliciting an IgG response
with a gB-binding magnitude comparable to that of a natural
infection (Baraniak et al., 2018a; Nelson et al., 2018b). However,
despite the gB titers induced, only a minimal virus-neutralizing
response was observed (Schleiss, 2018). The immunological
reasons for these results are not fully understood yet, but
several hypotheses have been proposed. The antigen employed
comprised the intraluminal region of the gB molecule, a domain
that generated non-neutralizing antibodies since it is not exposed
onto the surface of the virion (Schleiss, 2018). The sequence of
gB used in the vaccine is derived from a laboratory viral strain
that possesses neither the tropism nor the virulence of clinical
isolates (Nelson et al., 2018a). In addition, the sequence diversity
observed at the genomic level was proposed as a potential
issue for vaccine development (Renzette et al., 2017). Here, we
performed sequence analyses for all the envelope proteins of
HCMV and found that most of the proteins with a relevant
function are well conserved, with the exception of gN and gO.
While we investigated the relevance of antigenic variation for
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FIGURE 3 | Sequence alignment of the pentamer and gB complexes. Protein sequences were aligned with Clustal . All amino acids different from the reference
HCMV strain (Merlin) are highlighted in red. Thick lines inside the aligned sequences represent 100 amino acids. Regions with high sequence diversity are expanded
and shown in detail below the pictographic alignment. (A) Protein alignment of concatenated subunits of the pentamer complex (gHgLpUL128pUL130pUL131A).
(B) gB protein alignment where AD-2 and Furin cleavage site are expanded. Antigenic domains (AD) are highlighted in different colors.
vaccine design, we found that the pentamer is highly conserved
across all HCMV strains with a deposited sequence. The gB
antigen presents two main regions of variability across strains:
the Furin cleavage site and part of AD-2. However, the Furin
cleavage site is not supposed to be antigenic (Potzsch et al., 2011),
and only the conserved site of AD-2 is responsible for the
generation of neutralizing antibodies (Baraniak et al., 2018b,c).
Our analysis shows that both the pentamer and gB are well
conserved across strains. We hypothesize that the modest
efficacy observed in the recent clinical trials for an HCMV
Frontiers in Microbiology | www.frontiersin.org 5 May 2019 | Volume 10 | Article 1005
fmicb-10-01005 May 13, 2019 Time: 14:56 # 6
Foglierini et al. HCMV Envelope Glycoprotein Polymorphisms
vaccine (Baraniak et al., 2018a; Nelson et al., 2018b) does not
result from HCMV genomic polymorphism. The absence of a
strong neutralizing activity induced by the gB vaccine can be
explained by the immunodominant response generated against
AD-1 and AD-3. It has been shown that anti-AD1 antibodies
do not correlate with protection (Baraniak et al., 2018b), and
the humoral response against AD-1 upon natural infection
generates a very modest neutralizing activity (Speckner et al.,
1999). Moreover, AD-1 is also thought to mask AD-2, and part
of the latter is the target of neutralizing antibodies (Baraniak
et al., 2018b). Regarding AD-3, this domain is present in the
lumen of the virus; therefore, as previously discussed, it is unlikely
that antibodies generated against this domain will demonstrate a
neutralizing activity (Schleiss, 2018). In summary, we speculate
that engineering a gB vaccine lacking the antigenic domains
AD-1 and AD-3 might generate a higher neutralizing titer in
comparison to the vaccine candidate used in clinical trials.
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FIGURE S1 | Sequence alignment of gN and gO proteins. Amino acids different
from the reference HCMV strain (Merlin) are highlighted in red. Thick lines inside
the aligned sequences represent 100 amino acids. (a) Protein alignment of gN. (b)
Protein alignment of gO.
FIGURE S2 | Labeled gB phylogenic tree. Phylogenic analysis of the amino acid
sequences by Maximum Likelihood method for gB with name of the strains.
Bootstrap values equal or higher than 70% are shown.
FIGURE S3 | Labeled pentamer phylogenic tree. Phylogenic analysis of the amino
acid sequences by Maximum Likelihood method for the pentamer with name of
the strains. Bootstrap values equal or higher than 70% are shown.
TABLE S1 | HCMV strains used for the study.
DATA S1 | gB alignment file in fasta format.
DATA S2 | Pentamer alignment file in fasta format.
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